deltatrials
Terminated PHASE2 INTERVENTIONAL 2-arm NCT01824823

Afatinib After Chemoradiation and Surgery in Treating Patients With Stage III-IV Squamous Cell Carcinoma of the Head and Neck at High-Risk of Recurrence

A Randomized Placebo Controlled Phase II Trial of Afatinib (BIBW2992) as Adjuvant Therapy Following Chemoradiation in Patients With Head and Neck Squamous Cell Carcinoma at High Risk of Recurrence

Sponsor: ECOG-ACRIN Cancer Research Group

Conditions Head and Neck Squamous Cell Carcinoma
Interventions afatinib placebo
Updated 13 times since 2017 Last updated: Jun 13, 2023 Started: Jun 30, 2014 Primary completion: Dec 13, 2015 Completion: Dec 31, 2020
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Slow accrual

Other terminated trials from ECOG-ACRIN Cancer Research Group

More terminations from ECOG-ACRIN Cancer Research Group

Other Head and Neck Squamous Cell Carcinoma trials with similar outcome

Browse all Head and Neck Squamous Cell Carcinoma trials

A PHASE2 clinical study on Head and Neck Squamous Cell Carcinoma, this trial is terminated or withdrawn. The trial is conducted by ECOG-ACRIN Cancer Research Group and has accumulated 13 data snapshots since 2014. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Jan 2018 · 11 months · monthly snapshot~Jan 2018 – ~Jun 2018 · 5 months · monthly snapshot~Jun 2018 – ~Feb 2019 · 8 months · monthly snapshot~Feb 2019 – ~Nov 2020 · 21 months · monthly snapshot~Nov 2020 – ~Jan 2021 · 2 months · monthly snapshot~Jan 2021 – ~Feb 2021 · 31 days · monthly snapshot~Feb 2021 – ~Dec 2021 · 10 months · monthly snapshot~Dec 2021 – ~Jul 2023 · 19 months · monthly snapshot~Jul 2023 – ~Jul 2024 · 12 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 10 months · monthly snapshot

Change History

13 versions recorded

  1. Sep 2025 — Present [monthly]

    Terminated PHASE2

  2. Sep 2024 — Sep 2025 [monthly]

    Terminated PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE2

  4. Jul 2023 — Jul 2024 [monthly]

    Terminated PHASE2

  5. Dec 2021 — Jul 2023 [monthly]

    Terminated PHASE2

▶ Show 8 earlier versions

  1. Feb 2021 — Dec 2021 [monthly]

    Terminated PHASE2

    Status: Active Not Recruiting → Terminated

  2. Jan 2021 — Feb 2021 [monthly]

    Active Not Recruiting PHASE2

  3. Nov 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE2

  4. Feb 2019 — Nov 2020 [monthly]

    Active Not Recruiting PHASE2

  5. Jun 2018 — Feb 2019 [monthly]

    Active Not Recruiting PHASE2

  6. Jan 2018 — Jun 2018 [monthly]

    Active Not Recruiting PHASE2

    Status: Terminated → Active Not Recruiting

  7. Feb 2017 — Jan 2018 [monthly]

    Terminated PHASE2

  8. Jan 2017 — Feb 2017 [monthly]

    Terminated PHASE2

    First recorded

Jun 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • ECOG-ACRIN Cancer Research Group
  • National Cancer Institute (NCI)
Data source: Eastern Cooperative Oncology Group

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Adrian, United States , Akron, United States , Albany, United States , Ames, United States , Anchorage, United States , Ann Arbor, United States , Antigo, United States , Asheboro, United States , Atlanta, United States , Auburn, United States and 176 more locations